Stoke files for $86M IPO to take Dravet drug from preclinical to phase 3

Ed Kaye’s Stoke Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.